India’s TOP 500 Companies 2021

INDIA’S TOP 500 COMPANIES 2021 167 Experts’ View How would you summarize your company’s journey since its inception? What are some of the company’s key products and offerings? Bharat Parenterals Limited, like many others, had humble beginnings. But after few years, with sheer hardwork and dedication, the company gained increasing recognition in domestic as well as international markets. By 2006, the organisation was completely debt free and has remained so till date. Today, we export to more than 40 countries across 5 continents and have a domestic reach across 28 of 36 Indian states and union territories. Bharat Parenterals Ltd, with our partners, Auxillia Pharmaceuticals are the first to develop and launch Favipiravir Oral Suspension, which is a patent pending revolutionary drug being actively used in Mild to Moderate Covid-19 treatment. What are some of the company’s key ESG initiatives in recent years? At BPL, we have always been mindful of our impact on the Environment, as well as the community. Over the years, we have taken multiple steps to reduce our impact on the Environment. With 2 windmills and 900 KV of Solar Panels, 35% of our energy consumption is derived through Renewable Energy Sources. We also constantly educate our people on how to reduce carbon emissions, both at work and at home. Our Social initiatives include women empowerment, through various activities and competitions throughout the year. We are proud to say that 60% of our local workers are female, and over the years, many of them have run their own households, breaking the belief that only a man provides for the entire family. Our employees and workers are at the backbone of all initiatives, and most of them have also been given ESOPs, making them part of our growth journey, now and in the future. Our Employees also benefit from our education for all policy, which entitles them to claim education fees for their children. We also support our local communities by making several donations by helping them with real life problems. From building water tanks to installations of RO systems for safe clean water, we try and provide solutions to their problems. Our CSR foundation also provides free medicines to several NGOs. What is the company’s growth strategy over the next 3-5 years? Our growth strategy is multi-pronged. First, we have added a separate new unit in our current setup, which will double our capacity for Penicillin and Cephalosporin group of products and will enable us to qualify for PICS/EuGMP inspections. This in turn will open new markets from our existing manufacturing units. Second, we are expanding our current manufacturing unit to incorporate new production lines for Lyophilised products, Pre-filled Syringes and Emulsion based products. We will also have dedicated production lines for Hormones and Steroids, thus enabling us to enter new unexplored therapies. Lastly, but most importantly, we have started construction for our new US FDA Injectable facility, which is being built for the US and European Markets. We expect the facility to be commercialised by 2024. With a strong base in place, and our multi-pronged approach to the new and unexplored therapies as well as markets, we expect to grow aggressively in this decade. BHARAT PARENTERALS LIMITED Bhahim Desai CEO Dun & Bradstreet